Search

AstraZeneca has applied for a new indication listing for its BTK inhibitor, Acalabrutinib, in China.

TraderKnows
TraderKnows
08-28

On August 28, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration accepted AstraZeneca's application for Acalabrutinib Maleate Tablets.

Public information shows that Acalabrutinib (generic name: Acalabrutinib Capsules) is a Bruton's tyrosine kinase (BTK) inhibitor, previously approved in China for two indications. Based on pipeline information from AstraZeneca's official website, it is speculated that the new indication for Acalabrutinib application may be for the first-line treatment of chronic lymphocytic leukemia (CLL).

Acalabrutinib is a next-generation highly selective BTK inhibitor that inhibits its activity through covalent binding with BTK. In B cells, BTK signal activation is a critical pathway for B cell proliferation, transport, chemotaxis, and adhesion. Acalabrutinib was first approved in China in March 2023 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy; in September of the same year, Acalabrutinib was approved for a second indication, as monotherapy for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.

Business Cooperation Telegram Eng

Business Cooperation Skype ENG

Risk Warning and Disclaimer

The market carries risks, and investment should be cautious. This article does not constitute personal investment advice and has not taken into account individual users' specific investment goals, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their particular circumstances. Investing based on this is at one's own responsibility.

The End

Wiki

Stock price

The stock price is an important indicator of a company's value and market expectations. Investors can make more informed investment decisions by analyzing the stock price and related indicators. At the same time, companies should pay attention to stock performance, enhance their performance and market image, and maintain and improve shareholder value.

Organization

You Missed

Risk Warning

TraderKnows is a financial media platform, with information displayed coming from public networks or uploaded by users. TraderKnows does not endorse any trading platform or variety. We bear no responsibility for any trading disputes or losses arising from the use of this information. Please be aware that displayed information may be delayed, and users should independently verify it to ensure its accuracy.

Contact Us

Social Media

Region

Region

Contact